<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03227731</url>
  </required_header>
  <id_info>
    <org_study_id>UKwaZulu</org_study_id>
    <nct_id>NCT03227731</nct_id>
  </id_info>
  <brief_title>Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women</brief_title>
  <acronym>PrEP</acronym>
  <official_title>Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women An Open-Label Randomised Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of KwaZulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for the AIDS Programme of Research in South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council, South Africa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of KwaZulu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open Label randomized control study. To explore the safety of Truvada when used as PrEP
      during pregnancy and lactation. Pregnant women considered at risk for HIV infection and
      willing to participate in this randomized control study will be randomized to commencing PrEP
      in pregnancy and continued use throughout breastfeeding or deferred PrEP until breastfeeding
      cessation. All women will receive the standard of care for prevention of HIV and other
      sexually transmitted infections.

      Arm A: (Intervention): Standard HIV Prevention strategy PLUS a once daily dose of Truvada
      (FTC 200mg/TDF 300mg tablet) initiated in pregnancy, continuing until cessation of
      breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to
      continue PrEP post breastfeeding cessation.

      Arm B: (Control): Standard HIV Prevention strategy throughout pregnancy until cessation of
      breastfeeding PLUS the offer to initiate PrEP post breastfeeding cessation.

      Standard HIV prevention strategy includes risk reduction counselling, STI screening and
      treatment, condom promotion and inviting the sexual partner to receive HCT and referral for
      ART if he tests positive.

      Main Outcome Measure: Renal function, pregnancy outcomes, bone health and infant growth.

      Other Outcome Measure: Incident HIV infections, adherence to PrEP, drug resistance and
      mother-to-child transmission of HIV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      It is becoming increasingly evident that women remain vulnerable to HIV infection during
      pregnancy and even more so postdelivery. In a meta-analysis, using data from 19 international
      cohorts, Drake et al concluded that the pooled HIV incidence rate during pregnancy/postpartum
      was 3.8/100 PWY (95% CI 3.0-4.6): 4.7/100 PWY during pregnancy and 2.9/100 PWY postpartum. In
      earlier South African studies (2005-2009) investigators reported HIV seroconversion rates
      ranging from 1.3% to 3.0% in pregnancy [4-6]. Dinh et al in 2010-2012 reaffirmed the high
      seroconversion rate among pregnant women attending public health facilities in South Africa;
      3.3% (95% CI: 2.8%-3.8%) women seroconverted in pregnancy [7]. In an evaluation of PMTCT
      program indicators in KwaZulu-Natal in 2015 the HIV seroconversion rate among 78 906 pregnant
      HIV uninfected women was estimated as 1.8% (95%CI 1.0-2.9) in pregnancy and 5% (among 26 455
      breastfeeding women) in the postnatal period.

      Rationale:

      Truvada, an antiretroviral agent containing emtricitabine (200 mg) and tenofovir disoproxyl
      fumarate (300 mg) in a fixed-dose combination (FDC) tablet formulation is widely used in
      pregnant women as part of a combination treatment regimen and as prophylaxis to prevent
      mother-to-child transmission of HIV. Truvada is also the drug of choice in PrEP and currently
      recommended by the World Health Organization (WHO) for people at substantial risk of HIV
      infection (incidence &gt;3%). Pregnant women were excluded from participating in PrEP trials
      because of the lack of safety data in pregnancy. Available human and animal data suggest that
      TRUVADA does not increase the risk of major birth defects overall compared to the background
      rate and there are limited safety data for TDF/FTC when used in HIV uninfected pregnant
      women. In the past five years, PrEP trials have explored the use of Tenofovir alone or in
      combination with Emtricitabine in a once daily regimen, resulting in varying efficacy
      outcomes that have been largely associated with adherence. Much of the safety data have been
      generated in studies involving ART in HIV infected pregnant women. The majority of these
      studies indicate no added adverse effect of TDF on pregnancy outcomes. The few studies of TDF
      use in HIV uninfected women are treatment studies to prevent mother-to-child transmission of
      Hepatitis B and only 2 studies of TDF as PrEP use among women who subsequently fell pregnant
      post enrolment. However, exposure to TDF during pregnancy in these PrEP studies is limited
      since TDF was halted once pregnancy was diagnosed. Only a handful of studies have
      demonstrated the excretion of TDF into breastmilk and have concluded that these are
      relatively low doses of exposure to the infant. When women were given TDF 300mg/FTC 200mg as
      part of the triple drug regimen in Option B+ program in Malawi the Tenofovir concentrations
      in breastmilk were very low (breast milk/maternal plasma ratio = 0.08) [59]. Additional
      studies are needed to explore the effect of long term TDF exposure during breastfeeding on
      child growth and child health. Considering HIV uninfected women are encouraged to breastfeed
      for at least a year, studies exploring the long term effect of breastmilk exposure to TDF
      when used as PrEP in the mother, are needed.

      Goal:

      To explore the safety of Truvada when used as PrEP in combination with current
      recommendations for prevention of sexually transmitted infections in young women at
      substantial risk of HIV acquisition during pregnancy and lactation.

      Study Population:

      Pregnant women, at their first antenatal visit, HIV uninfected, without evidence of maternal
      or fetal complications and at risk for HIV infection.

      Sample Size:

      To compare the frequency and seriousness of adverse events in women receiving
      tenofovir/emtricitabine in pregnancy as opposed to women not receiving
      tenofovir/emtricitabine in pregnancy, we have based our sample size on the main clinically
      relevant pregnancy outcome. Although all pregnancy outcomes will be compared between the
      intervention (immediate PrEP) and control (deferred PrEP) groups, we based our sample size on
      the expected preterm delivery proportion among HIV uninfected women (South Africa 18.5%,
      Botswana 19%). A sample size of 421 in the Immediate PrEP group and 421 in the Deferred PrEP
      group (i.e. 842 in total) achieves 80% power to detect a non-inferiority margin difference
      between the group proportions of 0.075 or 7.5%. The reference group proportion (deferred
      PrEP) of pre-term delivery pregnancy outcome as a main clinically-relevant adverse event is
      0.185 or 18.5%.

      Study Design: An Open Label randomized control study. Pregnant women considered at high risk
      for HIV infection will be randomized to commencing PrEP in pregnancy with continued use
      throughout breastfeeding or deferred PrEP until breastfeeding cessation. Women in either
      group will receive the standard of care for prevention of HIV and other sexually transmitted
      infections.

      Study Duration:

      Mother: From the first antenatal visit in pregnancy until 18 months post-delivery.

      Infant: From birth until 18 months of age. Approximately 12 months for planned accrual and 24
      months for complete follow-up. The study period is expected to span 3 years.

      Study Products:

      Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose
      combination (FDC) tablet formulation and is proven safe for the prevention and treatment of
      HIV in non-pregnant and non-lactating women.

      Study Arms:

      Arm A: (Intervention) Standard HIV Prevention strategy PLUS a once daily dose of Truvada (FTC
      200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of
      breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to
      continue PrEP post breastfeeding cessation.

      Arm B: (Control) Standard HIV Prevention strategy throughout pregnancy until 18 months
      postdelivery PLUS the offer to initiate PrEP post breastfeeding cessation.

      Primary Objective:

      โข To compare the frequency and seriousness of specific adverse events related to TDF/FTC in
      women and their children in Arm A (exposure to TDF/FTC) and Arm B (no exposure to TDF/FTC)
      during pregnancy until breastfeeding cessation.

      Secondary Objectives:

        -  To estimate HIV incidence in women in ARM A with ARM B at delivery and at 18 months
           post-delivery.

        -  To determine the interdependency of adherence to a once daily oral TDF/FTC regimen and
           standard HIV prevention methods during pregnancy and postdelivery.

        -  To measure antiretroviral drug (TDF/FTC) level in women and their infants in association
           with adherence, safety and level of protection (plasma and breastmilk)

        -  To detect drug resistance among women who acquire HIV infection and correlate the
           treatment outcomes (after initiating immediate ARV treatment) with drug resistance

        -  To determine mother-to-child transmission of HIV among women who acquire incident
           infections during pregnancy and breastfeeding and the frequency of drug resistance in
           their infected babies
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Pregnant women considered at high risk for HIV infection will be randomized to commencing PrEP in pregnancy with continued use throughout breastfeeding or deferred PrEP until breastfeeding cessation. Women in either group will receive the standard of care for prevention of HIV and other sexually transmitted infections.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy Outcome-Preterm Deliveries</measure>
    <time_frame>Within 72 hours postdelivery</time_frame>
    <description>Number of preterm deliveries &lt; 37 weeks gestation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Mineral Density in mother and infant</measure>
    <time_frame>6 weeks postdelivery, and thereafter 6 monthly until week 74</time_frame>
    <description>Number of participants with decreased bone mineral density of hip and spine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pregnancy Outcome-Low Birth Weight</measure>
    <time_frame>Within 72 hours</time_frame>
    <description>Number of Low birth weight babies &lt;2500g</description>
  </primary_outcome>
  <other_outcome>
    <measure>Incident HIV infection</measure>
    <time_frame>Monthly during pregnancy and until 74 weeks postdelivery</time_frame>
    <description>Number of Incident HIV infections in women</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence to PrEP</measure>
    <time_frame>Monthly during pregnancy and until 74 weeks postdelivery</time_frame>
    <description>Number of women with &gt;90% adherence to PrEP</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">842</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Arm A (Intervention - Truvada)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard HIV Prevention strategy PLUS a once daily dose of Truvada (FTC 200mg/TDF 300mg tablet) initiated in pregnancy and continuing until cessation of breastfeeding or 18 months postdelivery whichever is earliest and thereafter the option to continue PrEP post breastfeeding cessation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Control - Standard of Care)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard HIV Prevention strategy throughout pregnancy until 18 months postdelivery PLUS the offer to initiate PrEP post breastfeeding cessation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Truvada</intervention_name>
    <description>Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.</description>
    <arm_group_label>Arm A (Intervention - Truvada)</arm_group_label>
    <other_name>emtricitabine 200mg/tenofovir disoproxil fumarate 300mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old.

          -  Confirmed HIV-1 uninfected.

          -  Willing to provide screening informed consent

          -  Currently pregnant

          -  Considered high risk for HIV infection

               -  Unprotected sex during pregnancy

               -  HIV status of current sexual partner is positive or unknown

          -  Results of HBV screening (HBsAg testing) available from specimen obtained within 30
             days prior to entry

          -  Plans to deliver in the study affiliated hospital

          -  Has no plans to move residence outside of the catchment area during the 18 months
             following delivery

        Exclusion Criteria:

          -  HIV infected

          -  &lt;18 years of age

          -  The following laboratory values from a specimen obtained within 30 days prior to study
             entry:

               -  Hemoglobin &lt;9.5 g/dL

               -  WBC &lt; 1500 cells/mm3

               -  ANC &lt; 750 cells/mm3

               -  Platelets &lt; 100,000 cells/mm3

               -  ALT &gt; 2.5 x upper limit of normal (ULN)

               -  Estimated creatinine clearance of &lt; 70mL/min using the Cockroft-Gault equation
                  for women: {([140 - age (years)] x [weight (kg)]) รท [72 x serum Cr (mg/dL)]} x
                  0.85

               -  Hepatitis B surface antigen (HBsAg) positive

          -  Participation in any other study

          -  In labour - at onset or beyond

          -  Serious illness (including TB) and/or hospitalization

          -  Receipt of TB treatment within 30 days prior to study entry

          -  Fetus detected with serious congenital malformation (ultrasound not required to rule
             out this condition)

          -  History of documented structural or conduction heart defect

          -  Social or other circumstances which would hinder long-term follow-up, in the opinion
             of the site investigator

          -  Currently incarcerated

          -  Substance or alcohol abuse (a score of &gt;8 on the WHO Alcohol Use).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dhayendre Moodley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of KwaZulu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dhayendre Moodley, PhD</last_name>
    <phone>+27(0)312604685</phone>
    <email>moodleyd1@ukzn.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vani Govender, BTechHons</last_name>
    <phone>+27(0)312601998</phone>
    <email>chettyv1@ukzn.ac.za</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of KwaZulu-Natal</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Reinertsen</last_name>
      <phone>+27(0)312608850</phone>
      <email>reinertsenk@ukzn.ac.za</email>
    </contact>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of KwaZulu</investigator_affiliation>
    <investigator_full_name>Dhayendre Moodley, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Preexposure prophylaxis</keyword>
  <keyword>safety</keyword>
  <keyword>HIV prevention</keyword>
  <keyword>pregnant women</keyword>
  <keyword>lactating women</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

